Published in Breast Cancer Res on June 29, 2009
Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov (2012) 3.88
The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer (2010) 1.80
Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res (2012) 1.47
Male breast cancer: an update in diagnosis, treatment and molecular profiling. Maturitas (2010) 1.11
Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther (2011) 1.02
ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells. Mol Cell Biol (2011) 1.00
Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol Ther (2014) 0.99
Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells. Mol Cancer Res (2011) 0.94
Potential Diagnostic, Prognostic and Therapeutic Targets of MicroRNAs in Human Gastric Cancer. Int J Mol Sci (2016) 0.94
Estrogen promotes breast cancer cell survival in an inhibitor of apoptosis (IAP)-dependent manner. Horm Cancer (2010) 0.93
Cell death signaling and anticancer therapy. Front Oncol (2011) 0.91
LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling. Cancer Res (2012) 0.91
Smac mimetic compounds potentiate interleukin-1beta-mediated cell death. J Biol Chem (2010) 0.88
The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer. Int J Breast Cancer (2011) 0.88
Induction of apoptosis by fucoidan in human leukemia U937 cells through activation of p38 MAPK and modulation of Bcl-2 family. Mar Drugs (2013) 0.87
Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization. Cancer Lett (2013) 0.85
Inhibitor of Apoptosis Proteins: Promising Targets for Cancer Therapy. J Carcinog Mutagen (2013) 0.83
A problem-solving education intervention in caregivers and patients during allogeneic hematopoietic stem cell transplantation. J Health Psychol (2013) 0.82
Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics. J Mammary Gland Biol Neoplasia (2012) 0.81
A novel antagonist to the inhibitors of apoptosis (IAPs) potentiates cell death in EGFR-overexpressing non-small-cell lung cancer cells. Cell Death Dis (2014) 0.78
Regulation of Apoptosis by HER2 in Breast Cancer. J Carcinog Mutagen (2013) 0.78
EDL-360: A Potential Novel Antiglioma Agent. J Cancer Sci Ther (2014) 0.76
Analysis of inhibitor of apoptosis protein family expression during mammary gland development. BMC Dev Biol (2010) 0.75
Discovering hidden connections among diseases, genes and drugs based on microarray expression profiles with negative-term filtering. PLoS One (2014) 0.75
Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death. Mol Cancer Ther (2015) 0.75
Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells. Oncotarget (2017) 0.75
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell (2000) 11.90
IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell (2007) 7.74
TNF-alpha induces two distinct caspase-8 activation pathways. Cell (2008) 6.81
A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science (2004) 4.95
Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep (2006) 4.15
Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat (2001) 3.77
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol (2005) 3.62
MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst (2000) 3.44
Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res (2000) 3.24
Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci U S A (2001) 3.19
The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis (2007) 3.16
IAP-targeted therapies for cancer. Oncogene (2008) 3.09
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res (2000) 2.86
The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem (2005) 2.47
XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. EMBO J (2005) 2.27
The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J Biol Chem (2000) 2.21
Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res (2003) 2.09
Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif (2007) 1.99
Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res (2001) 1.78
X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res (2004) 1.77
A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene (2005) 1.66
The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res (2007) 1.63
Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem (2002) 1.62
Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett (2007) 1.62
Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene (2004) 1.47
X-linked inhibitor of apoptosis functions as ubiquitin ligase toward mature caspase-9 and cytosolic Smac/DIABLO. J Biochem (2005) 1.37
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol (2006) 1.37
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol (2006) 1.37
Inhibitor of apoptosis proteins as targets for anticancer therapy. Expert Rev Anticancer Ther (2007) 1.34
Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther (2004) 1.33
Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics (2000) 1.33
Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J Clin Invest (2008) 1.29
Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res (2007) 1.23
Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res (2006) 1.22
Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol (2007) 1.21
Bim is an apoptosis sensor that responds to loss of survival signals delivered by epidermal growth factor but not those provided by integrins. J Biol Chem (2004) 1.20
Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer (2007) 1.19
Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif (2007) 1.15
Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Mol Cancer Ther (2008) 1.13
Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer (2006) 1.13
Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome. Urology (2007) 1.09
Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. Breast Cancer Res (2006) 1.09
Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res (2002) 1.07
Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther (2005) 1.07
Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica (2007) 1.04
Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann Oncol (2001) 1.04
XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer. Chin Med J (Engl) (2007) 1.01
Immunohistochemical detection of antiapoptotic protein X-linked inhibitor of apoptosis in mammary carcinoma. Hum Pathol (2007) 0.97
Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer (2008) 0.90
Molecularly targeted therapeutics for breast cancer. BioDrugs (2007) 0.82
Aberrant activation of notch signaling in human breast cancer. Cancer Res (2006) 3.92
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol (2010) 3.27
Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res (2010) 2.77
Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst (2007) 2.75
Mammary stem cells and breast cancer--role of Notch signalling. Stem Cell Rev (2007) 2.62
Ablation of beta1 integrin in mammary epithelium reveals a key role for integrin in glandular morphogenesis and differentiation. J Cell Biol (2005) 2.33
Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res (2012) 2.24
Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res (2008) 2.06
A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J Mammary Gland Biol Neoplasia (2012) 1.98
Beta1 integrins regulate mammary gland proliferation and maintain the integrity of mammary alveoli. EMBO J (2005) 1.94
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol (2009) 1.90
The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res (2004) 1.72
CSL-independent Notch signalling: a checkpoint in cell fate decisions during development? Curr Opin Genet Dev (2002) 1.68
Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem (2002) 1.62
Notch modulates Wnt signalling by associating with Armadillo/beta-catenin and regulating its transcriptional activity. Development (2005) 1.62
Bax exists in a dynamic equilibrium between the cytosol and mitochondria to control apoptotic priming. Mol Cell (2013) 1.60
The mammary gland "side population": a putative stem/progenitor cell marker? J Mammary Gland Biol Neoplasia (2005) 1.57
Idiopathic granulomatous mastitis: a 25-year experience. J Am Coll Surg (2007) 1.52
Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res (2005) 1.49
Rac1 links integrin-mediated adhesion to the control of lactational differentiation in mammary epithelia. J Cell Biol (2006) 1.48
Ductal carcinoma in situ of the breast. BMJ (2012) 1.47
Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia (2004) 1.47
The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets - improving meta-analysis and prediction of prognosis. BMC Med Genomics (2008) 1.41
Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Res (2009) 1.40
An integrin-ILK-microtubule network orients cell polarity and lumen formation in glandular epithelium. Nat Cell Biol (2013) 1.38
Origins of breast cancer subtypes and therapeutic implications. Nat Clin Pract Oncol (2007) 1.36
Spatial and temporal changes in Bax subcellular localization during anoikis. J Cell Biol (2003) 1.34
The C terminus of talin links integrins to cell cycle progression. J Cell Biol (2011) 1.33
Cell-matrix interactions in mammary gland development and breast cancer. Cold Spring Harb Perspect Biol (2010) 1.30
FAK engages multiple pathways to maintain survival of fibroblasts and epithelia: differential roles for paxillin and p130Cas. J Cell Sci (2009) 1.29
Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes (2009) 1.24
Interferon gamma induces translocation of commensal Escherichia coli across gut epithelial cells via a lipid raft-mediated process. Gastroenterology (2005) 1.23
Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions? Biochem Pharmacol (2004) 1.22
Desmosomal cadherin misexpression alters beta-catenin stability and epidermal differentiation. Mol Cell Biol (2005) 1.21
Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One (2013) 1.21
Bim is an apoptosis sensor that responds to loss of survival signals delivered by epidermal growth factor but not those provided by integrins. J Biol Chem (2004) 1.20
Wnt/beta-catenin signaling stimulates chondrogenic and inhibits adipogenic differentiation of pericytes: potential relevance to vascular disease? Circ Res (2007) 1.19
The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J Biol Chem (2003) 1.18
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat (2010) 1.18
Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res (2013) 1.16
Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Res (2008) 1.14
Molecular dissection of integrin signalling proteins in the control of mammary epithelial development and differentiation. Development (2009) 1.11
Risk determination and prevention of breast cancer. Breast Cancer Res (2014) 1.11
Wnt-Notch signalling crosstalk in development and disease. Cell Mol Life Sci (2014) 1.10
The embryonic transcription cofactor LBH is a direct target of the Wnt signaling pathway in epithelial development and in aggressive basal subtype breast cancers. Mol Cell Biol (2010) 1.10
Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. Breast Cancer Res (2006) 1.09
The extracellular matrix as an adhesion checkpoint for mammary epithelial function. Int J Biochem Cell Biol (2006) 1.09
Aurora A kinase regulates mammary epithelial cell fate by determining mitotic spindle orientation in a Notch-dependent manner. Cell Rep (2013) 1.07
Cell-matrix interactions during development and apoptosis of the mouse mammary gland in vivo. Dev Dyn (2002) 1.07
Alpha7 integrin mediates neurite outgrowth of distinct populations of adult sensory neurons. Mol Cell Neurosci (2005) 1.07
A role for the cytoskeleton in prolactin-dependent mammary epithelial cell differentiation. J Cell Sci (2004) 1.06
Breast cancer stem cells: something out of notching? Cancer Res (2010) 1.05
Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling. Breast Cancer Res (2013) 1.02
Enhanced Edar signalling has pleiotropic effects on craniofacial and cutaneous glands. PLoS One (2009) 1.02
Resistance to endocrine therapy: are breast cancer stem cells the culprits? J Mammary Gland Biol Neoplasia (2009) 1.02
A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity. Oncotarget (2014) 1.00
Disruption of a Quorum Sensing mechanism triggers tumorigenesis: a simple discrete model corroborated by experiments in mammary cancer stem cells. Biol Direct (2010) 1.00
Preconditioning injury-induced neurite outgrowth of adult rat sensory neurons on fibronectin is mediated by mobilisation of axonal alpha5 integrin. Mol Cell Neurosci (2007) 1.00
Stem cells in breast tumours: are they ready for the clinic? Eur J Cancer (2012) 1.00
Human breast epithelial stem cells and their regulation. J Pathol (2006) 1.00
P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal-like breast cancer. Stem Cells (2012) 0.99
High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic? Breast Cancer Res (2006) 0.98
Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity. Oncotarget (2013) 0.97
Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-α status. Cancer Res (2012) 0.96
Cooperation between Wnt and Notch signalling in human breast cancer. Breast Cancer Res (2007) 0.96
Biomarkers of dietary energy restriction in women at increased risk of breast cancer. Cancer Prev Res (Phila) (2009) 0.96
Early events in the anoikis program occur in the absence of caspase activation. J Biol Chem (2003) 0.95
Specific β-containing integrins exert differential control on proliferation and two-dimensional collective cell migration in mammary epithelial cells. J Biol Chem (2012) 0.95
Breast cancer stem cells and their role in resistance to endocrine therapy. Horm Cancer (2011) 0.95
Integrin signaling and mammary cell function. J Mammary Gland Biol Neoplasia (2003) 0.95
Insulin-like growth factor binding protein 5 and apoptosis in mammary epithelial cells. J Cell Sci (2003) 0.95
How adhesion signals reach a mitochondrial conclusion--ECM regulation of apoptosis. Curr Opin Cell Biol (2009) 0.93
Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Res (2002) 0.91
Molecular markers and therapeutic targets in ductal carcinoma in situ. Microsc Res Tech (2002) 0.91
Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway. Clin Cancer Res (2013) 0.90
Role for X-linked Inhibitor of apoptosis protein upstream of mitochondrial permeabilization. J Biol Chem (2009) 0.90
Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity. Cell Cycle (2013) 0.89
How integrins control breast biology. Curr Opin Cell Biol (2013) 0.89
P-cadherin signals through the laminin receptor α6β4 integrin to induce stem cell and invasive properties in basal-like breast cancer cells. Oncotarget (2014) 0.87
The Mcf1 toxin induces apoptosis via the mitochondrial pathway and apoptosis is attenuated by mutation of the BH3-like domain. Cell Microbiol (2007) 0.87
It's all in the details: methods in breast development and cancer. Breast Cancer Res (2009) 0.87
How integrins control mammary epithelial differentiation: a possible role for the ILK-PINCH-Parvin complex. FEBS Lett (2011) 0.86
Adenoviral-mediated gene transfer in two-dimensional and three-dimensional cultures of mammary epithelial cells. Methods Cell Biol (2002) 0.86
No association between cigarette smoking and incidence of plasma cell myeloma: a meta-analysis of 17 observational studies. Am J Hematol (2012) 0.86
Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res (2002) 0.86
Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status. PLoS One (2013) 0.85